Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD
Posted
Frank Vinluan (via MedCity News)
Verona Pharma’s COPD drug Ohtuvayre is a single small molecule that blocks two targets to bring patients both bronchodilation and anti-inflammatory effects. Verona executives contend their inhalable drug has key advantages over the last novel COPD medication, the orally administered roflumilast.
The post Verona Pharma Drug With Dual Mechanism Lands FDA Approval in COPD appeared first on MedCity News.
